Blessie E. Nelson, M.B.B.S., D.M.R.T.
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Investigational Cancer Therapuetics, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2011 | Christian Medical College, Vellore, Tamil Nadu, IN, DMRT |
| 2008 | Tribhuvan University, Kathmandu, NP, MBBS |
Postgraduate Training
| 2022-2023 | Research Fellowship, Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, Texas |
| 2021-2022 | Research Fellowship, Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, Texas |
| 2020-2021 | Clinical Fellowship, Medical Oncology, University of Texas Medical Branch, Galveston, Texas |
| 2019-2020 | Clinical Fellowship, Medical Oncology, University of Texas Medical Branch, Galveston, Texas |
| 2016-2019 | Clinical Residency, Internal Medicine, Sinai Hospital of Baltimore, Baltimore, Maryland |
| 2009-2011 | Clinical Residency, Radiation Oncology, Christian Medical College and Hospital, Vellore |
| 2008-2009 | Clinical Residency, Radiology Trainee, Christian Medical College and Hospital, Vellore |
| 2007-2008 | Clinical Internship, Universal College of Medical Sciences, Bhairahawa |
Licenses & Certifications
| 2023 | Diplomate in Medical Oncology, American Board of Internal Medicine |
| 2019 | Diplomate in Internal Medicine, American Board of Internal Medicine |
| 2019 | Texas Medical License |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - 2025
Other Professional Positions
Endowed Chief Fellow in Investigational Cancer Therapeutics Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - 2023
DEI Officer, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2023
Member-Transfusion Committee, The University of Texas Medical Branch, Galveston, TX, 2020 - 2021
Chief Fellow in Medical Oncology Fellowship Program, The University of Texas Medical Branch, Galveston, TX, 2020 - 2021
Antibiotic Stewardship Committee Officer, Sinai Hospital of Baltimore, Baltimore, Maryland, 2016 - 2019
Chief Resident, Christian Medical College and Hospital, Vellore, 2009 - 2011
Demonstrator, Christian Medical College and Hospital, Vellore, 2008 - 2009
Intramural Institutional Committee Activities
Member, Advanced Breast Cancer Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, IRB Review Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Co-Activity Director, Investigational Cancer Therapeutics Grand Rounds, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Co-Activity Director & Facilitator, Journal Club-Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Member, Program Evaluation Committee-Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Member, GME Diversity and Disparities Subcommittee, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Chief Fellow, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Patient Safety Officer, Institutional Patient Safety Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2023
Member, Medical Oncology Fellowship Program Committee, The University of Texas Medical Branch, 2020 - 2021
Chief Fellow, Fellow, Department of Hematology and Oncology, The University of Texas Medical Branch, 2020 - 2021
Member, Transfusion Comittee Member, The University of Texas Medical Branch, 2020 - 2021
Member, Patient Safety Quality Improvement Resident Council, Sinai Hospital, 2017 - 2019
Member, Antibiotic Stewardship Committee, Sinai Hospital, 2016 - 2019
Extramural Institutional Committee Activities
Member, SWOG, SWOG, 2026 - Present
Member, Editorial Board, Scientific Reports Journal, 2024 - Present
Member, Diversity Taskforce Working Group, Translational Breast Cancer Research Consortium (TBCRC), 2023 - Present
Organizer/Member, Annual Meeting at Association of Radiation Oncologists of India, Association of Radiation Oncologists of India, 2010
Editorial Activities
Editoral Board Member, Scientific reports, 2024 - Present
Guest Review Editor, Frontiers in oncology, 2023 - Present
Reviewer (Ad hoc), Molecular Cancer Therapeutics
Reviewer (Ad hoc), Journal of Hematology
Reviewer (Ad hoc), Frontiers in Urology
Reviewer (Ad hoc), Cancer medicine Journal
Reviewer (Ad hoc), eJHaem
Reviewer (Ad hoc), Nanomedicine Journal
Reviewer (Ad Hoc), Cureus
Reviewer (Ad hoc), Springer
Honors & Awards
| 2025 | SITC WIN Leadership Institute Program, Society in Cancer Immunotherapy Network |
| 2024 | Gateway for Cancer Research Award: Enhancing Inclusivity: Community-Focused Decentralization of Avapritinib Phase 2 Basket Study for Improved Access and Community Engagement |
| 2023 - 2024 | The Robert A. Winn Diversity in Clinical Trials Career Development Award |
| 2023 | The Robert G. Cox Memorial Endowed Merit Award in Molecularly Targeted Developmental Therapeutics by Conquer Cancer®, the ASCO Foundation, American Society of Clinical Oncology |
| 2022 | The Robert G. Cox Memorial Endowed Merit Award in Molecularly Targeted Developmental Therapeutics by Conquer Cancer®, the ASCO Foundation: ASCO Annual Meeting, American Society of Clinical Oncology |
| 2021 - 2023 | Endowed Fellow for IBC Foundation for Investigational Cancer Therapeutics Fellowship, University of Texas MD Anderson Cancer, Houston, TX, USA |
| 2021 | Nominated for Fellow of the Year, Department of Graduate Medical Education, University of Texas Medical Branch |
| 2021 | Chief Fellow Award, Department of Internal Medicine, Division of Hematology & Oncology,University of Texas Medical Branch |
| 2021 | Outstanding Fellow Award in UTMB Medical Oncology Fellowship Program, University of Texas Medical Branch |
| 2019 | Outstanding Academic Resident in 2019, Sinai Hospital of Baltimore, Maryland |
| 2016 | Ambulatory Doctor of the Month in July, Sinai Hospital of Baltimore, Maryland |
| 2016 | Outstanding Academic Resident, Sinai Hospital of Baltimore, Maryland |
| 2011 | First in Post Graduate Diploma in Medical Radiation Therapy, CMC |
| 2005 | Gold medalist for first rank in second phase of MBBS University exam, MBBS University,Nepal, India |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2023. FY23 IOTOX educational program lecture: Benign Hematology: Guidelines and Management of Immunotherapy mediated Anemia. Invited. Houston, Texas, US.
- 2023. Benign Hematology: Guidelines and Management of Immunotherapy Mediated Anemia. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2023. Morbidity & Mortality Grand rounds – Department of Investigational Cancer Therapeutics Drug related Autoimmune Hemolytic Anemia. Invited. Houston, Texas, US.
- 2023. Drug Related Autoimmune Hemolytic Anemia. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2023. A Phase I Trial of Bevacizumab and Temsirolimus in Combination with Valproic Acid in Advanced Solid Tumors: Research Trainee Day: MD Anderson. Conference. University of Texas MD Anderson Cancer Center, US.
- 2022. ICT Grand Rounds: Lighthousing Clinical Research in Early Phase Clinical Trials. Invited. Houston, Texas, US.
- 2022. ICT Faculty Rounds Presentation: Phase II and Pharmacodynamic Study of Tusamitamab Ravtansine in Combination with Cemiplimab in Solid Tumors. Invited. Houston, Texas, US.
- 2021. FGFR2 Inhibitor Toxicities with Gilbert Syndrome. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2021. ICI Related Ocular Myositis and Ocular Myasthenia-Like Symptoma. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2021. Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Eribulin in Patients with Advanced Malignancies – Department of Investigational Cancer Therapeutics, Breast and Sarcoma Medical Oncology. Invited. Houston, Texas, US.
- 2021. DRESS Syndrome. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2020. Clarifying the intent of cancer directed therapy and improving physician communication QI project. Poster. Research and QI competition Day. Galveston, Texas, US.
- 2020. Cancer screenings during the COVID-19 pandemic: an analysis of public interest trends. Conference. Texas Chapter American College of Physcians. Galveston, Texas, US.
- 2020. When A Cell Scowls at You: A Case of Hodgkins Lymphoma Presenting as Immune Thrombocytopenia: E-abstract presentation. Conference. Texas Chapter American College of Physcians. Galveston, Texas, US.
- 2020. What is the diagnosis? A Curious Case of Hairy Cell Leukemia Presenting with Venous Thromboembolism and without Splenomegaly. Poster. Texas Chapter American College of Physicians. Galveston, Texas, US.
- 2020. Speaker at Oncology Interest Group. Invited. The University of Texas Medical Branch. Galveston, Texas, US.
- 2019. Monthly Wellness Lectures. Invited. The University of Texas Medical Branch. Galveston, Texas, US.
Regional Presentations
- 2024. Impact of hematopoietic cell transplantation comorbidity index (HCT-CI) on AL Amyloidosis outcomes. Poster. Transplant and Cellular Therapy Conference. San Antonio, Texas, US.
National Presentations
- 2025. Genomic landscape in metaplastic breast cancer: Results from the AACR GENIE Database. Poster. American Association for Cancer Research Annual Meeting 2025. Chicago, IL, US.
- 2025. Decentralized Clinical Trials Collaborative Workshop. Panelist. Virtual. Los Angeles, California, US.
- 2024. Hepatitis C screening in Ambulatory setting and changes with Interventions QI project. Poster. Quality Improvement Project: Sinai Hospital of Baltimore. Baltimore, Maryland, US.
- 2023. Potentiating Local And Abscopal Antitumor Efficacy Through Radiation With FAP-CD40 DARPIN And Anti-PD1 Therapy. Poster. American Society for Radiation Oncology. San Diego, California, US.
- 2023. Intrapatient comparative efficacy of selective RET inhibitors using growth modulation index in patients with RET aberrant cancers. Conference. American Society of Clinical Oncology, US.
- 2023. RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study: The Robert G. Cox Memorial Endowed Merit Award in Molecularly Targeted Developmental Therapeutics by Conquer Cancer®, the ASCO Foundation. Conference. American Society of Clinical Oncology, US.
- 2023. First in human phase Ⅰ study of BMS-986299 as monotherapy and combined with nivolumab and ipilimumab in advanced solid tumors. Conference. American Society of Clinical Oncology. Chicago, Illinois, US.
- 2023. Predictors of survival outcomes in patients (pts) with advanced solid tumors treated with cellular therapies in early clinical trials. Conference. American Society of Clinical Oncology, US.
- 2023. Landscape of 4,506 pan-cancer samples harboring BRAFV600E mutations, and NTRK/RET Fusions from 137,401 adult patients with cancer: Clinical implications for tissue agnostic therapies. Poster. American Association of Cancer Research Annual Meeting. Orlando, Florida, US.
- 2023. Genomic landscape of 2128 thyroid cancers from the AACR GENIE database: Implications for targeted therapies: AACR 2023 Annual Meeting. Conference. American Association of Cancer Research. Orlando, Florida, US.
- 2023. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors: AACR 2023 Annual Meeting. Conference. American Association of Cancer Research Annual Meeting. Orlando, Florida, US.
- 2023. Landscape of 4,506 pan-cancer samples harboring BRAFV600E mutations, and NTRK/RET Fusions from 137,401 adult patients with cancer: Clinical implications for tissue agnostic therapies: AACR 2023 Annual Meeting. Conference. American Association of Cancer Research, US.
- 2022. Effect of Immunotherapy and Time-of-Day Infusion Chronomodulation On Survival in Advanced Cancers. Conference. American Society of Clinical Oncology, US.
- 2022. Phase Ib Study of Selinexor and Eribulin Combination in Advanced Solid Tumors and Triple Negative Breast Cancer: The Robert G. Cox Memorial Endowed Merit Award in Molecularly Targeted Developmental Therapeutics by Conquer Cancer®, the ASCO Foundation. Conference. American Society of Clinical Oncology, US.
- 2022. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Poster. Transplant and Cellular Therapy Conference (TCT). Orlando, Florida, US.
- 2022. Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in AL Amyloidosis. Poster. Transplant and Cellular Therapy Conference (TCT). San Antonio, Texas, US.
- 2022. : B-RAF V600E harboring non-melanoma cancers treated with Vemurafenib monotherapy and in combination with Everolimus/Sorafenib/Crizotinib/Paclitaxel+ Carboplatin: A pooled analysis of five phase 1/2 studies. Poster. American Association of Cancer Research Annual Meeting. New Orleans, Louisiana, US.
- 2021. Autologous hematopoietic stem cell transplantation for AL amyloidosis refractory to induction therapy. Invited. American Society of Hematology (ASH). Atlanta, Georgia, US.
- 2021. Autologous hematopoietic stem cell transplantation for AL amyloidosis refractory to induction therapy. Invited. Houston, Texas, US.
- 2021. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Invited. American Society of Hematology (ASH), US.
- 2021. Twin T ADC Trial with Traztuzumab Deruxtecan + Sacituzumab Govitecan. Conference. Gilead, US.
- 2021. Using Quality Oncology Practice Initiative Data to Enhance Medical Oncology Ambulatory Clinic Practices. Poster. American College of Surgeons (ACS) Quality and Safety Conference, US.
- 2021. Corticosteroid use and its impact on the efficacy of immunotherapy in multiple tumor types: A single institution, retrospective cohort study. Conference. American Society of Clinical Oncology (ASCO). Chicago, Illinois, US.
- 2019. Expecting the unexpected: Immunotherapy and Myasthenia Gravis. Conference. American Society of Clinical Oncology. Chicago, Illinois, US.
- 2019. Quality Improvement Conference Presentation. Invited. Baltimore, Maryland, US.
- 2018. Penicillin Allergy Testing and Cost Effectiveness and Alternatives QI project. Poster. Quality Improvement Project: Sinai Hospital of Baltimore. Baltimore, Maryland, US.
- 2018. Management of pericardial effusion. Invited. Sinai Hospital of Baltimore. Baltimore, Maryland, US.
- 2017. Delayed Diagnosis of Diabetic Ketoacidosis Secondary to SGLT2 Inhibition. Poster. Maryland American College of Physcians Annual Associates Conference. Baltimore, Maryland, US.
- 2017. Critical Care Management of Acalculous Cholecystitis. Invited. Sinai Hospital of Baltimore. Baltimore, Maryland, US.
- 2017. Updates in IDSA Guidelines of HAP. Invited. Sinai Hospital of Baltimore. Baltimore, Maryland, US.
- 2016. Management of Anemias, Ambulatory Lecture. Invited. Sinai Hospital of Baltimore. Baltimore, Maryland, US.
International Presentations
- 2011. Academic Basic Sciences Lecture Series for Radiation Therapy. Invited. CMC Hospital, IN.
- 2010. Role of Radiotherapy and patient outcomes in the management of meningiomas. Poster. 32nd National conference of the Association of Radiation Oncologists of India. Patna, IN.
Formal Peers
- 2019. Curriculum for Emotional Wellness for Clinical Fellows. Galveston, Texas, US.
- 2008. Curriculum Teaching and Mentorship of Medical Students, Residents, and Fellows at the School of Radiation Therapy, IN.
Grant & Contract Support
| Date: | 2024 - 2026 |
| Title: | Enhancing Inclusivity: Community-Focused Decentralization of Avapritinib Phase 2 Basket Study for Improved Access And Community Engagement |
| Funding Source: | GATEWAY FOR CANCER RESEARCH |
| Role: | PI |
| ID: | G-24-1200 |
| Date: | 2023 |
| Title: | The Robert G. Cox Memorial Endowed Merit Award in Molecularly Targeted Developmental Therapeutics by Conquer Cancer® |
| Funding Source: | ASCO Foundation |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Nelson BE, Janku F, Fu S, Dumbrava EE, Hong DS, Karp DD, Naing A, Rodon J, Tsimberidou AM, Murthy R, Sheth RA, Amaria RN, Conley AP, Damodaran S, Raghav KPS, Carapanceanu N, Singh MP, Carapanceanu V, Pezeshki A, Leontovich AA, Kreider BL, Tung D, Varterasian M, Khazaie K, Piha-Paul SA. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clin Cancer Res 31(18):3864-3875, 2025. e-Pub 2025. PMID: 40643985.
- Nelson, BE, O'Brien, S, Sheth, RA, Hong, DS, Naing, A, Zhang, X, Xu, A, Hamuro, L, Suryawanshi, R, McKinley, D, Novosiadly, R, Piha-Paul, SA. Phase i study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors. Journal for immunotherapy of cancer 13(1), 2025. e-Pub 2025. PMID: 39824531.
- Mouabbi, JA, Meric-Bernstam, F, Nasrazadani, A, Nelson, BE, Salem, B, Kushnarev, V, Tkachuk, A, Sotova, M, Polyakova, M, Baranov, O, Turova, P, Chernyshov, K, Kotlov, N, Brown, JH, Clayton, P, Sarachakov, A, Postovalova, E, Bagaev, A, Tripathy, D, Layman, RM. The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
- Silva DJ, Nelson BE, Rodon-Ahnert J. Decentralized Clinical Trials in Early Drug Development - A Framework proposal. Journal of Immunotherapy and Precision Oncology 2024, 2024. e-Pub 2024.
- Nardo, Gouda M, Nelson BE, Barretto C, Subbiah: V. Strategies for Mitigating Selective RET inhibitor Related Adverse Events in Patients with RET-altered Cancers. Cell Reports Medicine 2024, 2024. e-Pub 2024.
- Nelson E, Roszik J, Nardo M, Noia Barretto CM, Ahmed J, Campbell E, Johnson AM, Piha-Paul SA, Glitza I, Weathers S, Cabanillas M, Javle M, Meric-Bernstam F, Subbiah V. RAF-inhibitor Re-challenge Therapy in BRAF Aberrated Pan-Cancers: RE-RAFFLE study: Molecular Cancer 2024. Molecular Cancer, 2024. e-Pub 2024.
- Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist 28(12):e1100-e1292, 2023. e-Pub 2023. PMID: 37311055.
- Nardo M, Yilmaz B, Nelson BE, Torres HA, Wang LS, Granwehr BP, Song J, Dalla Pria HRF, Trinh VA, Glitza Oliva IC, Patel SP, Tannir NM, Kaseb AO, Altan M, Lee SS, Miller E, Zhang H, Stephen BA, Naing A. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist 28(8):714-721, 2023. e-Pub 2023. PMID: 36952233.
- Gouda MA, Nelson BE, Buschhorn L, Wahida A, Subbiah V. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications. Clin Cancer Res 29(15):2753-2760, 2023. e-Pub 2023. PMID: 37061987.
- Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer 129(14):2201-2213, 2023. e-Pub 2023. PMID: 37016732.
- Nelson BE, Reddy NK, Huse JT, Amini B, Nardo M, Gouda M, Weathers SP, Subbiah V. Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma. NPJ Precis Oncol 7(1):47, 2023. e-Pub 2023. PMID: 37231247.
- Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol 7(1):19, 2023. e-Pub 2023. PMID: 36801912.
- Nelson E, Adashek JJ, Sheth AA, Subbiah V. Molecular Cancer Therapeutics: Abscopal Effect: Identifying Biomarkers and Histologies for Success. AACR, 2023. e-Pub 2023.
- Nelson BE, Ejezie CL, Stephen BA, Nardo M, Campbell E, Gong J, Hong DS, Fu S, Yap TA, Murphy MB, Piha-Paul S, Daver NG, Rojas-Hernandez CM, Naing A. Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. J Hematol 11(3):113-120, 2022. e-Pub 2022. PMID: 35837373.
- Greiner B, Tipton S, Nelson B, Hartwell M. Cancer screenings during the COVID-19 pandemic: An analysis of public interest trends. Curr Probl Cancer 46(1):100766, 2022. e-Pub 2022. PMID: 34304883.
- Nelson E, Adashek JJ, Lin SH, Subbiah V. Wiley: Cancer Medicine: On Target Methods to Induce Abscopal Phenomenon for Off-Target Effects: From Happenstance to Happenings. Cancer Med. 2022, 2022. e-Pub 2022.
- Nelson BE, Hong A, Okereke I, Markowitz A, Willis M, Muthukumarana PV, Nawgiri R. Non-neoplastic inflammatory pseudotumor of the lung after immunotherapy for melanoma: A diagnostic pitfall on fine needle aspiration biopsy of lung. Diagn Cytopathol 49(10):1150-1154, 2021. e-Pub 2021. PMID: 34331523.
- Nelson BE, Tipton S, Venkatesan R. Early Onset Neutropenia due to Rituximab Therapy in Mantle Cell Lymphoma: A Case Report. J Hematol 10(3):136-138, 2021. e-Pub 2021. PMID: 34267851.
- Cordova J, Nelson B, Brizendine AM, Iqbal F, Venkatesan R. CD5+ Diffuse Large B-Cell Lymphoma With Leukemic Transformation: A Rare Case With Central Nervous System Involvement, Treated With R-CHOP and Intrathecal Methotrexate/Cytarabine. Cureus 13(6):e15838, 2021. e-Pub 2021. PMID: 34327076.
- Greiner B, Lee M, Nelson B, Hartwell M. The pink elephant in the room: Declining public interest in breast cancer and the impact of marketing efforts. J Cancer Policy 28:100287, 2021. e-Pub 2021. PMID: 35559903.
- Nelson B, Warfield D, Mejia CV, Walker JP. Rare presentation of growing teratoma syndrome in patient with remote history of testicular cancer resection. J Surg Case Rep 2021(1):rjaa600, 2021. e-Pub 2021. PMID: 33542815.
- Nelson BE, Hong A, Dekmezian M, Jana B. Standard-Dose Rituximab as Effective Therapy for Treating Malignancy-Related Hemophagocytic Lymphohistiocytosis in the Eldery: A Case Report. Case Rep Oncol 14(2):1066-1070, 2021. e-Pub 2021. PMID: 34326743.
- Nelson BE, Hong A, Iqbal F, Jana B. A unique case of hemolytic-uremic syndrome secondary to enteropathogenic E Coli. Clin Case Rep 8(12):2625-2628, 2020. e-Pub 2020. PMID: 33363792.
- Nelson B, Brizendine AM, Gietzen R, Venkatesan R. Case of HER2neu+ Invasive Pleomorphic Lobular Carcinoma With Response to Conventional Neoadjuvant Chemotherapy: A Viable Option for an Exceedingly Rare Breast Cancer Type. Cureus 12(10):e11108, 2020. e-Pub 2020. PMID: 33240704.
- Nelson B, Hong A, Iqbal F, Venkatesan R. An Advanced AIDS Patient With CD4 <20 and Plasmablastic Lymphoma Achieving Complete Response With the V-EPOCH Regimen. Cureus 12(6):e8641, 2020. e-Pub 2020. PMID: 32685310.
Review Articles
- Nelson, BE, Naing, A, Fu, S, Sheth, RA, Murthy, R, Piha-Paul, SA. Potentiating intratumoral therapy with immune checkpoint inhibitors. Immuno-Oncology and Technology 25, 2025. e-Pub 2025. PMID: 39981134.
- Silva, DJ, Nelson, BE, Rodon Ahnert, J. Decentralized Clinical Trials in Early Drug Development—A Framework Proposal. Journal of Immunotherapy and Precision Oncology 7(3):190-200, 2024. e-Pub 2024. PMID: 39219999.
- Nelson BE, Meric-Bernstam F. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors. Annu Rev Med 75:31-48, 2024. e-Pub 2023. PMID: 37758237.
- Nardo, M, Gouda, MA, Nelson, BE, Barreto, CN, Slade, JH, Poullard, A, Zafereo, M, Hu, MI, Cabanillas, ME, Subbiah, V. Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers. Cell Reports Medicine 4(12), 2023. e-Pub 2023. PMID: 38118420.
- Nelson BE, Adashek JJ, Sheth AA, Subbiah V. Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers. Mol Cancer Ther 22(6):706-716, 2023. e-Pub 2023. PMID: 37259805.
- Nelson BE, Adashek JJ, Lin SH, Subbiah V. The abscopal effect in patients with cancer receiving immunotherapy. Med 4(4):233-244, 2023. e-Pub 2023. PMID: 36893753.
- Nelson BE, Adashek JJ, Lin SH, Subbiah V. On target methods to induce abscopal phenomenon for Off-Target effects: From happenstance to happenings. Cancer Med 12(6):6451-6465, 2023. e-Pub 2023. PMID: 36411943.
- Nelson BE, Hong A, Jana B. Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review. Front Oncol 11:705294, 2021. e-Pub 2021. PMID: 34422659.
Other Articles
- Nelson E, Hong A, Iqbal F, Jana B A unique case of hemolytic‐uremic syndrome secondary to enteropathogenic E Coli. Clin Case Rep, 2022.
- Nelson E, Hong A, Iqbal F, Nawgiri R, Okereke I, Markowitz A Non-neoplastic inflammatory pseudotumor of the lung after immunotherapy for melanoma: A diagnostic pitfall on fine needle aspiration biopsy of lung. Diagn Cytopathol, 2021.
- Cordova, Nelson BE, Brizendine A, Pacheco D, Willis M, Markowitz A Breast cancer-associated paraneoplastic stiff person syndrome: anastrozole monotherapy insufficient for symptom improvement. F1000Research, 2021.
- Nelson E, Warfield D, Mejia C, Walker JP Growing Teratoma Syndrome masquerading as an abdominal mass. J Surg Case Rep, 2021.
- Nelson E, Brizendine A, Gietzen R, Venkatesan R Treating invasive pleomorphic lobular carcinoma with dual HER-2 targeted therapy, are we one step closer to a cure, 2021.
- Nelson BE, Hong A, Dekmezian M, Jana B Standard-dose rituximab as effective therapy for treating malignancy related hemophagocytic lymphohistiocytosis in a geriatric female, 2021.
Abstracts
- Nelson BE. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. AACR 31(18), 2024. e-Pub 2025.
- Nelson BE. Genomic landscape in metaplastic breast cancer: Results from the AACR GENIE database. AACR Annual Meeting 2025, 2024. e-Pub 2024.
- Nelson E, Roszik J, Noia Barreto CM, Nardo M, Ahmed J, Campbell E, Johnson A, Piha-Paul SA, Glitza IC, Weathers SS, Cabanillas ME, Javle MM, Meric-Bernstam F, Subbiah V. RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study: The Robert G. Cox Memorial Endowed Merit Award in Molecularly Targeted Developmental Therapeutics by Conquer Cancer®, the ASCO Foundation, 2023. e-Pub 2023.
- Nelson BE. Complementary Medicine Strategies for Symptom Management in Breast Cancer Survivors: A Comprehensive Review of Evidence-Based Interventions. Society for Integrative Oncology.
Book Chapters
- Nelson, BE, Oo, TH, Rojas Hernandez, CM. Autoimmune Hemolytic Anemia Post Immune Checkpoint Inhibitors, 227-234, 2025.
- Nelson BE, Rondon-Ahnert J. Handbook of Targeted Cancer Therapy and Immunotherapy: Breast Cancer, 1st edition. In: Handbook of Targeted Cancer Therapy and Immunotherapy: Breast Cancer. 1. Wolters Kluwer, 2022.
- Nelson BE. Intern/Resident Survival Guide for Internal Medicine Residency Program 2018, 2016.
Letters to the Editor
- Nelson, BE, Roszik, J, Ahmed, J, Barretto, CN, Nardo, M, Campbell, E, Johnson, A, Piha-Paul, SA, Glitza, IC, Weathers, S, Cabanillas, ME, Javle, M, Meric-Bernstam, F, Subbiah, V. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers. Molecular cancer 23, 2024.
- Nelson, BE, Subbiah, V. Predicting the Abscopal Phenomenon-Reply. Molecular cancer therapeutics 23: 250, 2024.
Patient Reviews
CV information above last modified July 22, 2026